Improving treatments for chronic toxoplasmosis infections
Optimizing CDPK1 inhibitors for chronic toxoplasmosis
This study is looking for new medicines to help people with chronic infections from the Toxoplasma gondii parasite, especially those with weakened immune systems or pregnant women, by testing a special type of drug that could better target the infection when it’s hiding in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11044174 on NIH RePORTER |
What this research studies
This research focuses on finding new medications to effectively treat chronic infections caused by the Toxoplasma gondii parasite, which can remain dormant in the body and reactivate when the immune system weakens. The project aims to identify and optimize CDPK1 inhibitors, a class of compounds that may target the chronic stage of the infection. By testing these inhibitors in laboratory settings, the researchers hope to develop safer and more effective treatments for patients suffering from chronic toxoplasmosis. This work is particularly important for immunocompromised individuals and pregnant women who are at higher risk of complications.
Who could benefit from this research
Good fit: Ideal candidates for this research include immunocompromised individuals and pregnant women who are at risk of chronic toxoplasmosis.
Not a fit: Patients who are not infected with Toxoplasma gondii or those with acute infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for chronic toxoplasmosis, reducing the risk of severe health complications.
How similar studies have performed: While there have been efforts to develop new treatments for Toxoplasma gondii, this specific approach using CDPK1 inhibitors is novel and has not been extensively tested.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Sibley, L. David — Washington University
- Study coordinator: Sibley, L. David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.